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Bisphosphonates are known for their strong inhibitory effect on bone resorption. Their inﬂuence on bone
formation however is less clear. In this study we investigated the spatio-temporal effect of locally
delivered Zoledronate on peri-implant bone formation and resorption in an ovariectomized rat femoral
model. A cross-linked hyaluronic acid hydrogel was loaded with the drug and applied bilaterally in
predrilled holes before inserting polymer screws. Static and dynamic bone parameters were analyzed
based on in vivo microCT scans performed ﬁrst weekly and then biweekly. The results showed that the
locally released Zoledronate boosted bone formation rate up to 100% during the ﬁrst 17 days after im-
plantation and reduced the bone resorption rate up to 1000% later on. This shift in bone remodeling
resulted in an increase in bone volume fraction (BV/TV) by 300% close to the screw and 100% further
away. The double effect on bone formation and resorption indicates a great potential of Zoledronate-
loaded hydrogel for enhancement of peri-implant bone volume which is directly linked to improved
implant ﬁxation.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
The human skeleton is constantly renewed and repaired by the
bone remodeling process, a well-coordinated sequence of
osteoclast-mediated bone resorption and osteoblast-mediated
bone formation [1,2]. Anti-catabolic drugs, such as bisphospho-
nates (BPs), can slow down this process and shift the balance be-
tween bone formation and resorption activity by selectively
affecting osteoclast function [3]. Osteoclasts are considered to be
the main target for BPs as only this cell type can liberate and
internalize mineral bound BPs during the resorption process [4,5].
However, effects of BPs on cells of the osteoblast lineage have also
been described, which raises the question if BPs can also enhance
bone formation activity [6,7]. In vitro experiments have shown that
low concentrations of BPs can protect osteoblasts and osteocytes
against apoptosis [8,9], stimulate mineralized bone nodule forma-
tion [10], and have a beneﬁcial effect on osteoblast differentiation
and protein synthesis [11]. Speciﬁcally for Zoledronate, the most
potent bisphosphonate used in clinics today, an improvedtation 19, 1015 Lausanne,
660.
ioletti).mineralization and proliferation of human osteoblast-like cells has
been demonstrated [12]. However, conﬂicting results can also be
found showing that BPsmight inhibit mineralization and osteoblast
growth, induce osteoblast apoptosis, and inhibit protein pre-
nylation in osteoblasts in a dose-dependent manner [7,13]. Taken
together, these ﬁndings suggest that BPs might, in addition to their
known anti-resorptive effect, also have the ability to stimulate bone
formation.
BPs are usually administered orally or intravenously. Local
application is of particular interest in cases where existing bone
needs to be preserved and augmented whilst avoiding the known
side effects related to systemic administration [14,15]. Several
in vivo studies have shown that a local delivery of BPs can enhance
peri-implant bone density [16,17], implant ﬁxation [18e22], and
the repair of bony defects [23,24] in animal models and humans.
Furthermore BPs have been shown to preserve bone allografts
[25,26] as well as bone sites affected by osteonecrosis [27].
Currently published studies are mostly based on static analysis
techniques like single CT/microCT scans, histology or pull-out/
push-out tests performed after euthanasia of the animals
[18,22,28]. These techniques do not allow a separate investigation
of the dynamic bone formation and bone resorption processes. Few
studies can be found that looked at dynamic bone parameters after
a systemic administration of BPs, but they did not show enhanced
U. Kettenberger et al. / Biomaterials 35 (2014) 9995e100069996bone formation activity in humans nor in animals [29,30]. Some
studies even demonstrated reduced bone formation and a sup-
pressed activity of pre-existing bone-forming surfaces at medium
to high doses of BPs [31e35].
Therefore, the aim of the present study is to investigate the
spatio-temporal effect of locally delivered Zoledronate on peri-
implant bone remodeling using the so-called dynamic histo-
morphometry. This previously developedmicroCT-based technique
enables us to quantitatively measure the average outcome of bone
formation and resorption over long time periods [36,37], allowing
an investigation of the so far unclear effect of locally applied BPs on
the dynamic bone formation processes. Understanding the effects
of Zoledronate and how it interacts with normal bone healing is
important when it comes to designing drug delivering implants
and materials. The active range, the time delay, and duration of the
BPs' effects (very local versus widespread, fast versus slow, long
term versus short-term effects) are crucial for targeting speciﬁc
bone sites, as well as certain phases of bone healing.
2. Materials and methods
2.1. General study design
Custom-made polymeric miniature screws were implanted bilaterally in the
femoral condyles of ovariectomized (OVX) rats. Unlike metal implants, these screws
are visible on microCT scans without creating image disturbing artifacts. A hydrogel
based drug delivery system was used to release Zoledronate into the peri-implant
bone stock. During surgery, the hydrogel was inserted into the predrilled screw-
hole before screw implantation. The study included 3 experimental groups with 4
animals assigned to each group. In the ﬁrst group, the hydrogel was loaded with 5 mg
Zoledronate (ZoleGel-group); in the second group, unloaded hydrogel was used
(Gel-group); and in the third group, no hydrogel was inserted (Control-group)
before screw implantation. Time-lapsed in vivo microCT scans of the animals were
performed for close monitoring of the bone response to the implantation and how it
is altered by the bisphosphonates delivery. A time line of the study is shown in Fig. 1.
2.2. Hydrogel preparation
A commercially available cross-linked hyaluronic acid (Termira AuxiGel™,
Stockholm, Sweden) was used as the drug delivery system for the BPs because this
gel had already been shown to be a suitable material for delivering drugs such as
growth factors to bone [38e41]. The crosslinking of the hydrogel is achieved by
mixing a hyaluronan derivative (component A) with a PVA cross-linker (component
B). First, an aqueous solution containing 2 mg/ml Zoledronate (Art.-Nr. ALX-430-
153-0000, Enzo Life Sciences, Farmingdale, USA) was prepared. The exact drug
dose was ensured by mixing precisely weighed and measured amounts of Zoledr-
onate and distilledwater. All solutions were sterile ﬁltered and themixing of the gels
was performed under sterile conditions. Five parts of the Zoledronate solution were
mixed with 3 parts of component A and 2 parts of component B for the ZoleGel-
group. The Zoledronate solutionwas replaced by bi-distilledwater for the Gel-group.
The resulting gels were allowed to settle for 1 h before ﬁlling the capillary pistons of
a positive displacement pipette (Microman®, Gilson, Middleton, USA) with 5 ml gel
each. The capillaries were pulled off the pipette with the gel inside and left 1 h for
settling. Then they were sterile packed in plastic tubes and frozen at 20 C.
2.3. Animal model
All animal procedures were approved by the local animal care and use com-
mittee (license no. 2508.1, EXPANIM, SCAV, Epalinges, Switzerland). Twelve 14 weekAge rats 
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Fig. 1. Timeline of the study; the rats are ovariectomized at an age of 17 weeks followed by t
were performed to conﬁrm the bone loss after OVX, 6 more were performed after the screold virgin female rats were received from Janvier Labs (Saint-Berthevin, France) and
acclimatized in the animal facilities for 3 weeks. All rats were housed 4 per cage
under 12 h light to 12 h dark cycles at 22 C room temperature with 55% humidity.
They were fed with a standard rodent diet (KLIBA NAFAG 3436, Provimi Kliba AG,
Switzerland) and tap water at libitum. After ovariectomy (OVX), food intake was
limited to 50 g per kg bodyweight per day. Sterilized hay, paper tunnels andwooden
stickswere offered as cage environment enrichment. The animals were fed in groups
and equal nutrition of all animals was ensured by close monitoring and regular
weighing.
2.4. Surgical procedures
2.4.1. Ovariectomy
The rats were ovariectomized bilaterally at an age of 17 weeks and a weight of
293 ± 11 g to induce an estrogen deﬁciency related bone loss [42]. We used a dorsal
approach similar to the procedure described by Alghamdi et al. [43]. Buprenorphine
(Temgesic®, Reckitt Benckiser AG, Wallisellen, Switzerland) was administered sub-
cutaneously before surgery and every 8 h for the ﬁrst 48 h after surgery for pain
relief. Paracetamol (Dafalgan 500 mg effervescent tablet, UPSA Bristol-Myers Squibb
SA, Baar, Switzerland) was added to the drinking water of the rats for 5 days. The
skin incisions were closed with running subcuticular sutures (Vinyl 5.0, Ethicon,
Somerville NJ, USA) so that the rats did not have to be kept in separate cages after the
surgery. No antibiotics were given.
2.4.2. Screw implantation
Screws were implanted when the rats were aged 22 weeks and weighed
338 ± 18 g. One miniature screw was implanted in each femoral condyle under
isoﬂurane anesthesia with Buprenorphine to avoid intraoperative pain. The sur-
gery was done under aseptic conditions. The rat was prepared for surgery and the
ﬁrst leg was ﬁxed on a special table with the knee in a ﬂexed position. A skin
incision of 1e2 cm was made on the lateral side of the distal femoral end and the
muscles were blunt dissected in order to expose the condyle. One hole with a
diameter of 1.2 mm and 3.5 mm length was drilled unicortically in the condyle
with a motorized dentist's drill (DEC 100, Nobelcare, Sweden). The cortex was pre-
tapped to avoid deformation and damage to the polymer screws. The drilled hole
was rinsed with saline solution and surgical vacuum was used to remove bone
particles. As a next step, the hydrogel was inserted in the predrilled hole with a
positive displacement pipette before implanting a miniature screw (Fig. 2). The
screws with a thread length of 3 mm and a diameter of 1.4 mmwere custom made
from radiopaque polyetheretherketone (RISystem, Davos, Switzerland) with a
100 nm titanium coating to mimic the interface with a standard orthopedic screw.
After implanting the screw, the fascia of the muscle was closed with resorbable
sutures (Vinyl 5.0). The skin was closed with interrupted subcuticular sutures
(Vicryl 5.0) before performing the same procedure at the contralateral femur. The
rat was placed in a heated incubator for post-surgical recovery. The post-OP
medication and care was similar to the procedure after ovariectomy described
above.
2.5. MicroCT imaging, data processing and analysis
2.5.1. In vivo microCT imaging
In vivomicroCT scans (Skyscan 1076, Bruker microCT, Kontich, Belgium) of only
the right femur were performed one day before OVX and one day before screw
implantation in order to conﬁrm the bone loss caused by the estrogen deﬁciency.
Both femurs were then scanned at days 3, 10, 17, 31, 45, and 58 after screw im-
plantation for the dynamic histomorphometry. According to literature, no bone
damage due to radiation can be expected after 8 consecutive microCT scans [44]. The
animals were kept under isoﬂurane anesthesia during the scans to avoid motion
artifacts. The rats were euthanized at the time of the last microCT scan with an
intraperitoneal injection of pentobarbital (Esconarkon, Streuli Pharma SA, Uznach)
while under anesthesia.3026
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Fig. 2. Hydrogel insertion in the predrilled bone hole located in the femoral condyle of the rat; the gel is inserted in the hole via a positive displacement pipette before implanting
the screw.
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The parameters for the scans assessing the bone loss before screw implantation
were the following: 0.5mm aluminum ﬁlter, voltage 60 kV, current 167 mA, exposure
time 480 ms, rotation step 0.4 . The peri-implant bone after screw insertion was
scanned with different parameters adapted to the density of the screw: 0.5 mm
aluminum ﬁlter, voltage 80 kV, current 120 mA, exposure time 400 ms, rotation step
0.5 . The spatial resolution of all scans was 18.4 mm. Two polymerehydroxyapatite
phantoms with known mineral density were scanned under the same conditions as
the rats and served for a calibration of the bone mineral density (BMD) and tissue
mineral density (TMD) measurement histograms. The reconstruction of the pro-
jection images was done with NRecon and GPURecon Server (Bruker microCT,
Kontich, Belgium). A ring artifact correction of 4 and a beam hardening correction of
20% for the scans assessing bone loss and 30% for the peri-implant bone scans were
set to improve the image quality. The reconstruction output was stacks of cross-
sections in 8-bit bitmap format.
2.5.3. Assessment of the estrogen deﬁciency induced bone loss
The scans taken before OVX and before screw implantation were analyzed with
the software CTan (Bruker microCT) to conﬁrm the induced bone loss. A volume of
interest (VOI) with a length of 4 mm was deﬁned proximal to the growth plate
located in the femoral condyle. Cortical and trabecular regions were selected
automatically with a customized algorithm before analyzing the morphometric
parameters as well as the BMD of the trabecular region and the TMD of the cortical
region.
2.5.4. MicroCT-based dynamic histomorphometry
The microCT datasets were used to perform dynamic histomorphometry, a
technique that is based on the registration and comparison of two consecutiveFig. 3. Main steps of the dynamic histomorphometry. First, pairs of microCT scans from c
automated algorithm and the time points are compared voxel by voxel by assigning different
a last step, 4 layered VOIs of 368 mm each are created and analyzed separately for static anmicroCT scans [36,37]. Bone was considered to be resorbed if it was present on the
ﬁrstmicroCT scan and not on the second, whereas bonewas considered to be formed
if it was present on the second scan and did not appear on the ﬁrst. Bone which
appeared in both scans was considered to be quiescent. In this way, bone remodeling
can be monitored in three dimensions over long periods of time without the need to
euthanize the animals.
Image processing for the dynamic histomorphometry was done with Amira®
(FEI Visualization Sciences Group, Burlington, USA) and CTan. In the femoral
condyle, a VOI of 4.5 mm in height around the screw was manually deﬁned with
CTan for all animals. Using an automated algorithm, the background and the patella
were removed and the dataset size was reduced to facilitate image processing. Then
all datasets were loaded into Amira® for further processingwith a custom script. The
script ﬁrst super positioned all original gray value images using the built-in regis-
tration function and their correlations as a similarity measure. Each dataset was
registered with the image from the previous time step. All images were transformed
into the coordinate system of the ﬁrst image using the built-in standard interpola-
tionmethod and the datasets were ﬁltered with a median-based 3D noise-reduction
ﬁlter. Next, a VOI containing only trabecular bone was automatically deﬁned on the
ﬁrst dataset and adapted manually so that it would also ﬁt consecutive scans which
are slightly different due to ongoing bone remodeling. Then, for all datasets, the VOI
was binarized with a threshold of 80. By comparing consecutive scans voxel by
voxel, resorbed, formed, and quiescent bone regions were identiﬁed and assigned
one of three gray values. Two additional gray values were assigned to the screw and
the bone marrow. These images were saved and loaded into CTan. The static and
dynamic bone parameters around the screwweremeasured in four layers of 368 mm
(20 voxels) (Fig. 3). The static bone parameters bone volume fraction (BV/TV),
trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular separation
(Tb.Sp), and structure model index (SMI) were analyzed for a complete assessmentonsecutive time points are registered and segmented. The cortex is removed with an
gray values to bone present only on the ﬁrst, only on the second or on both datasets. In
d dynamic bone parameters.
U. Kettenberger et al. / Biomaterials 35 (2014) 9995e100069998of the bone structure changes. The volume-based bone formation rate (BFR) and
bone resorption rate (BRR) were chosen as representative parameters as their
calculation is robust and not as sensitive to registration inaccuracies as the surface-
based parameters. The bone formation rate is given in percent per day (%/d) and
calculated as the ratio of formed bone volume to quiescent bone volume divided by
the number of days between the two scans. The bone resorption rate is calculated as
the ratio of resorbed bone volume to quiescent bone volume divided by the days
between the scans.
2.6. Histology
The rat femurs were dissected just after euthanasia and ﬁxed in 4% para-
formaldehyde solution before dehydrating them in a series of ethanol solutions with
ascending concentration (70%, 80%, 90%, 95% and 100%). After clearing the samples
in toluol, they were embedded by inﬁltrationwith methylmethacrylate 99% (MMA),
bis(tert-butylcyclohexyl) peroxydicarbonate (Perkadox 16) and dibutylphtalate
(DBP). All agents were purchased from SigmaeAldrich (St. Louis, US). After poly-
merization during 3 weeks at room temperature, the samples were cut with a
diamond-coated inner diameter saw (Leica SP 1600, Leica Microsystems, Wetzlar,
Germany) to slices of around 200 mm thickness. Those slices were glued with acrylic
glue (Loctite 401, Henkel, Düsseldorf, Germany) to custom-made opaque PMMA
microscope slides (Semadeni, Ostermundigen, Switzerland) and ground to around
60 mm thickness with a grinding machine (Pedemax-2, Struers, Willich, Germany).
Finally, the surface of the slides was etched with 0.7% formic acid (Applichem,
Gatersleben, Germany) before staining it with toluidine blue (VWR, Dietikon,
Switzerland). Images were taken with an upright light microscope (DM 5500, Leica
Microsystems, Wetzlar, Germany).
2.7. Statistics
Statistical testing was done with Matlab (Mathworks, Natick, MA, USA). Values
lying outside an interval of 1.5 times the quartile range were identiﬁed as outliers
and excluded. The results of the OVX scans were analyzed with a paired t-test after
performing a Lilliefors test for a normal distribution. In case the normal distribution
could not be conﬁrmed, a Wilcoxon singed rank test was used. The static and dy-
namic bone parameters were tested for signiﬁcance with a non-parametric Kruskal
Wallis ANOVA followed by a Tukey's HSD (Honestly Signiﬁcant Difference) test since
not all groups followed a normal distribution and nor did they all have equal
variance.
3. Results
3.1. Clinical observations
All rats tolerated both surgeries well and returned to normal
activity post-surgery. One rat from the ZoleGel-group had to be
euthanized 4 weeks after screw implantation due to a chol-
angiocarcinoma that was unrelated to the study. The results from
this animal were still included in the analysis as the statistical tests
did not identify them as outliers when compared with the other
animals of the same group. The limited food intake allowed a
controlled weight gain in the animals; their ﬁnal mean weight was
372 ± 21 g.
3.2. Assessment of the estrogen deﬁciency induced bone loss
The in vivo microCT scans conﬁrmed that the rats had a
diminished BMD, enlarged marrow cavities, and a signiﬁcantly
lower trabecular bone volume only 35 days after OVX (Table 1). This
was shown by the decreasing BV/TV and Tb.N, and the increasing
Tb.Sp. No signiﬁcant changes could be detected for the Tb.Th. TheTable 1
Changes in bone parameters following OVX. Bone within the ﬁrst 4 mm proximal to the f
difference between the mean values before and after OVX to the mean value before OVX
Cancellous bone parameters
BMD [g/mm3] BV/TV [%] SMI [] Tb.Th
Before OVX 0.32 ± 0.03 33.4 ± 3.9 1.19 ± 0.25 0.14 ±
35 Days after OVX 0.23 ± 0.04 20.8 ± 4.9 1.79 ± 0.27 0.15 ±
Mean change 28% 38% 50% 7%
p Value 0.000 0.000 0.001 0.126rising SMI showed that the trabecular bone had shifted from a
mainly plate-like structure to a more rod-like structure that is
typical of osteoporotic bone [45]. However, the estrogen deﬁciency
had no short-term inﬂuence on the cortical bone. No changes could
be detected in the cortical thickness (C.Th); the TMD of the cortex
increased slightly by 2%.3.3. MicroCT-based dynamic histomorphometry
A total of 138 microCT scans were analyzed for the dynamic
histomorphometry, of which 2 had to be excluded due to motion
artifacts. The sample size of the analyzed groups varied from 5 to 8
after removal of the outliers. The hyaluronic acid hydrogel used as a
drug delivery system did not show any effect on the analyzed bone
parameters. No signiﬁcant differences were found between the
Control-group and the Gel-group at any time. Volume rendered
comparisons of two time points for one femur from the Gel-group
and one from the ZoleGel-group are shown in Fig. 4.3.3.1. Static bone parameters
Two main bone regions can be distinguished in the results: the
inner layer (0e368 mm from screw surface) and part of the second
layer (368e736 mm) reﬂect the bone reaction to the screw im-
plantation. The two outer layers (736e1472 mm) are not affected by
the implant and show stable bone parameters.
All experimental groups showed a clear gain in BV/TV, Tb.Th,
and Tb.N in direct proximity to the screw between day 3 and day 10
after screw implantation (Figs. 5e7). The Tb.Sp and the SMI
decreased in accordance with the other bone parameters, which
indicates amore compact bone structure (Figs. 8 and 9). This gain in
bone mass continued for the ZoleGel-group until day 17 and pla-
teaued at a BV/TV of around 55% until the end of the study. In the
Control- and the Gel-groups, the initial bone gainwas followed ﬁrst
by a rapid and then later by amoderate bone loss. The ﬁnal BV/TV in
those two groups was around 13%. The effect of Zoledronate
diminished with increasing distance from the screw surface. The
trabecular parameters of the ZoleGel-group showed that the gain
in bone volume further from the screw was mainly caused by an
increasing Tb.N and a decreasing Tb.Sp (Figs. 6 and 7). The Tb.Th in
the outer two layers was identical for all groups and constant
throughout the whole study (Fig. 8).3.3.2. Dynamic bone parameters
In direct proximity to the screw, a constant low BRR of around
2e3%/d was seen for the ZoleGel-group throughout the whole
study (Fig. 10). The Control- and Gel-groups initially showed (days
3e10) an equally low BRR followed by a high peak of around 12%/
d from days 10 to 17. From then onward, the BRR diminished until
the study end point and reached a value equal to the ZoleGel-group
for the last period analyzed, which was 45e58 days after screw
implantation. In the outer three layers, the BRR in the Control- and
Gel-groups was initially very high (8e10%/day) compared to theemoral growth plate was analyzed. The mean changes were calculated as ratio of the
.
Cortical bone parameters
[mm] Tb.Sp [mm] Tb.N [1/mm] TMD [g/mm3] C.Th [mm]
0.01 0.32 ± 0.09 2.39 ± 0.32 1.09 ± 0.03 0.55 ± 0.01
0.02 0.92 ± 0.25 1.39 ± 0.31 1.11 ± 0.03 0.56 ± 0.02
191% 42% 2% 0%
0.000 0.000 0.008 0.133
Fig. 4. Three-dimensional visualization of the peri-implant bone indicating bone formation and resorption sites of two samples, one from the Gel-group (top), one from the
ZoleGel-group (bottom). The data were acquired by a comparison of pairs of consecutive microCT scans as described in Section 2.5.4. The analyzed trabecular region of the bone is
shown in light gray, red and green, the screw in dark gray and the cortex in transparent.
U. Kettenberger et al. / Biomaterials 35 (2014) 9995e10006 9999ZoleGel-group (3e5%/day). This difference evened out over time
and was no longer signiﬁcant from days 31 to 58.
Unlike the effect of Zoledronate on bone resorption, its inﬂuence
on bone formation was small. The results of the BFR showed that
the implantation of the screw induced an early peak in bone for-
mation in the inner two layers in all groups (Fig. 11). The BFR in the
Control- and Gel-groups was characterized by a peak of around
20%/d from days 3 to 10, followed by an almost constant low BFR of0 10 20 30 40 50 600
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Fig. 8. Trabecular thickness measured in 4 layers around the screw, the gray asterisks indicate the signiﬁcant differences between ZoleGel-group and Gel-group, the black ones
between Control-group and ZoleGel-group.
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Fig. 9. Structure model index measured in 4 layers around the screw, the gray asterisks indicate the signiﬁcant differences between ZoleGel-group and Gel-group, the black ones
between Control-group and ZoleGel-group.
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Fig. 10. Bone resorption rate measured in 4 layers around the screw, the gray asterisks indicate the signiﬁcant differences between ZoleGel-group and Gel-group, the black ones
between Control-group and ZoleGel-group.
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screw implantation and showed a constant BFR of around 5%/d. The
ZoleGel-group differed in this region only from days 3 to 10, where
it showed a small but signiﬁcant bone formation peak of 9%/d in the
region from 736 to 1104 mm respective 6%/d from 1104 to 1472 mm.
3.4. Histology
Histology results showed that the hyaluronic acid hydrogel was
fully degraded after 58 days of implantation since hydrogel resi-
dues could no longer be detected in neither the Gel- nor the
ZoleGel-groups (see Fig. 12). The screws were well osteointegrated
in all groups; no signiﬁcant amounts of ﬁbrotic tissue could be
detected close to the screw surfaces. In the Control- and the Gel-
groups, new bone matrix was deposited only in direct proximity
to the screws; no new bone formation could be detected further
away. Only small periosteal callus formationwas visible around the
screw heads of the Control- and Gel-groups, the bone structure
within those calli was still immature. In contrast, a large amount of
newly formed bone was detected close to and further away from
the screw surface in the ZoleGel-group. This newly formed bone
also showed a woven structure typical of immature bone with an
irregular arrangement of the collagen ﬁbers, a large cell number
and reduced mineral content. In the ZoleGel-group, signiﬁcant
periosteal callus formation was found even far from the implan-
tation site. Normal-shaped osteoclasts and foreign body giant cells
were present in all three groups, but to a much lower extent in the
ZoleGel-group than in the other two groups. The bone lining os-
teoblasts seemed to be more activated in the ZoleGel-groupcompared to Control- and Gel-groups. The histology showed a
signiﬁcantly enhanced peri-implant bone density in the ZoleGel-
group. The newly formed bone was not fully remodeled in all
groups, whereas the bone remodeling in the ZoleGel-group
seemed to be less advanced than in the other two groups.
4. Discussion
The main goal of the present study is to investigate the spatio-
temporal effect of locally delivered Zoledronate on peri-implant
bone remodeling based on time-lapsed microCT scans. In this
context, a cross-linked hyaluronic acid hydrogel was used as drug
delivery material.
The signiﬁcant new result of this study is an up to 100% increase
of the early bone formation rate caused by locally delivered
Zoledronate that accompanies an efﬁcient inhibition of peri-
implant bone resorption. In this way, Zoledronate initially boosts
bone formation and later on helps to preserve the newly formed
bone. It is the ﬁrst in vivo study unambiguously demonstrating the
positive effect of Zoledronate on bone formation. This result opens
new possibilities for local delivery of this drug as well as for the
understanding of its global effect on bone remodeling.
MicroCT-based histomorphometry was chosen for this study
as it has been shown to be a very suitable technique for the
quantitative analysis of three-dimensional bone formation and
bone resorption rates over long in vivo time periods [36].
Obtaining data from multiple time points without having to
euthanize the animals is a key advantage of a longitudinal
study compared to the traditional two-dimensional histology-
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Fig. 11. Bone formation rate measured in 4 layers around the screw, the gray asterisks indicate the signiﬁcant differences between ZoleGel-group and Gel-group, the black ones
between Control-group and ZoleGel-group.
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based technique compared to histology is that bone resorp-
tion rate can be quantiﬁed in a direct manner that is very
useful when studying the effect of anti-resorptive drugs such as
BPs [36]. Metal induced artifact issues that are typically related
to CT scans and complicate the analysis of peri-implant bone
were overcome in the present study by using radiopaque PEEK
screws.
In order to understand the inﬂuence of the BPs on the peri-
implant bone remodeling, it is important to have a look at the
normal bone healing as it was found in the Control-group. First,
the changes in bone structure caused by the estrogen deﬁciency
are consistent with those reported in the literature and conﬁrm
the success of the OVX [31]. The results from the histo-
morphometry performed after screw implantation showed that
the bone reaction to the trauma caused by the screw implantation
took place principally in the two innermost layers (the “bone-
healing-zone”, 0e736 mm from the screw surface). This zone was
characterized by a large increase in bone formation rate during
the ﬁrst 17 days after the surgery up to a distance of 736 mm from
the screw surface. This early peri-implant bone formation is in
accordance with literature where it was shown to be the result of
the so-called static osteogenesis [46,47]. Osteogenic cells and a
new calciﬁed matrix are therefore deposited after only a few days
on the cement line created on the implant surface [48]. This rapid
deposition of calciﬁed matrix restores the continuity of the bone
structure, even if the mechanical competence of the woven bone
is lower than that of mature remodeled bone due to the random
orientation of the collagen ﬁbers [49]. No microCT-based studiescould be found conﬁrming bone formation this early next to an
implant.
The woven structure of the newly formed bone in the Control-
group was conﬁrmed in the present study by a decrease in SMI
and an increase in Tb.N and Tb.Th that accompanied the gain in BV/
TV in the bone-healing-zone from days 3 to 10. Woven bone is
reported to be progressively remodeled and substituted by mature
bone with a trabecular structure and delimiting marrow spaces
later on [50], a process that also removes bone debris and necro-
tized bone caused by the implant bed preparation [51]. In the
present study, the remodeling was initiated by a signiﬁcant loss in
bone volume in the bone-healing-zone that started 10 days after
screw implantation in the Control-group.
Another interesting ﬁnding from the Control-group is the
initially high, and then progressively decreasing, BRR in the outer
two layers that are not in contact with the screw (the “bone-
remodeling-zone”). This phenomenon can be explained by the
initial rapid bone loss phase induced by the estrogen deﬁciency of
the animals that terminates 3e4 months after OVX [42]. The bone
loss is even enhanced in this study by the growth of the animals
that results in a “ﬂow” of the screw and the surrounding volume of
interest towards the less trabecularized diaphyseal region. Nor-
mally, the growth of rats slows down and ceases around 26 weeks
of age [52], this corresponds in this study with day 31 after screw
implantation. When comparing bone resorption with formation in
the Control-group, it can be seen that, beside the early bone for-
mation peak, the BRR clearly exceeded the BFR in all bone regions
most of the time and leveled out only towards the end of the study.
This imbalance resulted in a steady bone loss in the bone-
Fig. 12. Toluidine blue stained ground sections from the Control-group (left), the Gel-group (middle) and the ZoleGel-group (right). The white asterisks in the darker blue regions
indicate immature, non-remodeled bone with an irregular structure and large amounts of cells, the white arrows on brighter blue regions show mature trabecular bone with less
cells and a regular structure.
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control animals.
The Gel-group did not show any statistically different results
compared to the Control-group, therefore the chosen hydrogel can
be considered not to have any inﬂuence on peri-implant bone
remodeling. It was resorbed completely during the study without
leaving any visible residuals, as conﬁrmed by histology.
The locally delivered Zoledronate interfered with the normal
healing and remodeling process at a very early stage as demon-
strated in the ZoleGel-group. An increase of up to 100% of the BFR
was seen from days 3 to 17 in the bone-healing-zone and from days
3 to 10 in the bone-remodeling-zone. Later on during the study, no
more differences could be detected between the groups. This result
suggests that Zoledronate is only inﬂuencing bone formation dur-
ing the ﬁrst “ﬂush” with the drug where bone-forming cells are
either in contact with the gel or exposed to Zoledronate in solution.
The direct contact could allow them to incorporate the drug via
ﬂuid phase endocytosis, an uptake mechanism for Zoledronate that
has been described by Thompson et al. [53]. BPs are known to be
rapidly cleared from the circulation and absorbed to bone mineral
surface [54]. The fast uptake in the bone can explainwhy no further
Zoledronate effect on bone formation could be detected later on in
the study. This is because osteoclasts are the only cells that can
liberate and incorporate BPs once they are bound to bone mineral
[4]. It remains unclear if the initial boost in bone formation is
caused by a direct stimulation of the osteoblast activity, or by un-
known indirect coupling effects. Arnoldi et al. recently found a
higher level of cellular proliferation and osseous differentiation at
an early time point around implants coated with ﬁbrinogen and
loaded with a very low dose of Zoledronate [55]. This ﬁndingsupports the theory that Zoledronate can have a direct anabolic
effect on bone formation. Published in vitro studies are not
conclusive as they demonstrate that Zoledronate can have positive
as well as negative results on osteoblasts, depending on the dose
and study design [11,12,56]. Orriss et al. showed that the Zoledro-
nate dose has to be increased 10- to 100-fold to achieve the same
inhibitory effect on osteoblasts when those are cultured on dentin
slides, a ﬁnding that supports the theory that absorbed BPs are
signiﬁcantly less effective on osteoblasts [13].
Since Zoledronate is an anti-resorptive agent, the drug is ex-
pected to mainly inﬂuence bone resorption. In the present study,
this was shown by the signiﬁcantly reduced BRR in the drug treated
animals. The strong resorption peak seen in the Control-group was
not at all present in the bone-healing-zone of the ZoleGel-group in
which the BRR remained at a constant low level. A slightly higher
but still constant BRR level could be found in the bone-remodeling-
zone of the ZoleGel-group. The investigated time period was too
short to detect a clear end of the drug effect on bone resorption.
However, static and dynamic bone parameters of the last analyzed
time points and periods suggested a diminishing drug effect with a
slightly increasing BRR and decreasing differences between the
groups, particularly in the bone-remodeling-zone.
Looking at the spatial effect of the locally delivered Zoledronate,
this study revealed that the majority of the effects of BPs occur at a
distance of up to 736 mm around the screw, which corresponds to
the earlier deﬁned bone-healing-zone. Tests with hydrogel loaded
with hydroxyapatite-particles (size 200 nm) that give the gel a light
radiopacity (data not shown) revealed that the gel is located within
a range of 0e600 mm around the screw. Therefore, it can be
assumed that bone is in direct contact with the Zoledronate-loaded
U. Kettenberger et al. / Biomaterials 35 (2014) 9995e10006 10005gel within the region that shows the strong drug effect. These re-
sults suggest that it may be possible to control the range of action of
the Zoledronate-loaded gel via its penetration depth in bone. This is
a promising approach as the penetration depth can be adapted by
altering the mechanical properties of the gel or the volume of gel
inserted into the implant bed. However, a signiﬁcantly weaker drug
effect was also shown for the bone-remodeling-zone that is not in
contact with the gel. This ﬁnding suggests that a small part of the
released Zoledronate diffuses through the bone despite its high
afﬁnity to mineral and its fast absorption in bone surfaces.
The boost in initial bone formation, the effective inhibition of
the bone resorption in the bone-healing-zone, and the stabilization
of the bone loss in the bone-remodeling-zone resulted in a BV/TV
that was up to 300% higher compared to the Control-group in the
bone-healing-zone and up to 100% higher in the bone remodeling-
zone. The reduction of SMI and Tb.Sp as well as the increase Tb.N
conﬁrmed a shift from osteoporotic towards a more normal bone
structure. This is a very positive ﬁnding as an augmented micro-
structure of peri-implant bone is linked to improved implant
anchorage [57e59]. The gain in bone volume and therefore in
mechanical resistance might nevertheless be partly compensated
for by the less mature bone structure that was present 2 months
after screw implantation, as conﬁrmed by histology in the present
study. The SMI of 0.6 that characterized the bone in the bone-
healing zone of the ZoleGel-group at day 58 compared to an SMI
of 2.6 in the Control-group conﬁrmed that the very compact woven
bone had not yet remodeled. Findings in similar studies provide
enough evidence to show that Zoledronate treated bone can
enhance implant ﬁxation despite the reduced mechanical compe-
tence of the immature bone structure [18,19,22]. Furthermore,
Amanat et al. showed with an indentation study that Zoledronate
has no inﬂuence on the intrinsic mechanical properties of healing
bone [60].
The present study has inherent limitations. The microCT-based
dynamic histomorphometry averages bone formation and resorp-
tion rate over the time period between two scans what makes the
results sensitive to the chosen time points for the scans [36]. In this
study bone formation and bone resorption have to be interpreted as
gain and loss of mineralized bone tissue since the microCT cannot
analyze the bone on a cellular level. Furthermore, the age of the rats
was not ideal due to the fact that the end of the initial OVX related
bone loss phase and the cessation of bone length growth occurred
during the experimental phase. In future studies, histology should
be performed at early time points for a better understanding of how
Zoledronate enhances very early peri-implant bone formation. It
might also be useful to prolong the experimental phase in order to
assess when bone maturity is reached in the ZoleGel-group. In this
study, only one drug dose of 5 mg per implant was tested. A future
doseeresponse study could help to investigate the dose-
dependency of the present ﬁndings.
In summary, the quickly degradable hydrogel used in this study
appeared to be a very suitable drug delivery system for BPs. The
texture and material properties of the gel allowed for an easy and
precise application, combined with a deep penetration of the bone
tissue that signiﬁcantly increased the range of action of the drug.
Numerous studies have shown that BPs released from coatings stay
highly localized and result in a very thin layer of dense bone around
implants which is not ideal for implant ﬁxation [61,62]. This is not
the case in the present study where an increased bone volume
could be shown all over the analyzed trabecular region. The present
study also demonstrated a positive inﬂuence of Zoledronate on
early bone formation in addition to its known anti-resorptive ac-
tion. This effect seems to be supported by a fast release of the small
BP molecules from the highly porous hydrogel, another point in
favor of the use of hydrogels as drug-delivery systems for BPs.5. Conclusions
The present study was able to show that Zoledronate delivered
from a quickly degrading hydrogel can boost early bone formation
and later on efﬁciently inhibit peri-implant bone resorption close to
an implant. It can also stabilize bone loss away from an implant in
an OVX rat model. This process signiﬁcantly enhanced bone mass
and improved bone micro-structure in the treated peri-implant
bone during the two months post-implantation that were stud-
ied. This is a positive ﬁnding since a reinforced bone structure is
directly linked to improved implant ﬁxation. The presented
approach using Zoledronate-loaded hydrogel for implant bed
preparation is highly promising, especially for patients suffering
from low quality bone, though more studies are needed.Acknowledgments
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